Compass Therapeutics (CMPX) Cash & Current Investments (2023 - 2025)
Historic Cash & Current Investments for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $220.5 million.
- Compass Therapeutics' Cash & Current Investments rose 6214.09% to $220.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $220.5 million, marking a year-over-year increase of 6214.09%. This contributed to the annual value of $127.3 million for FY2024, which is 1650.98% down from last year.
- Compass Therapeutics' Cash & Current Investments amounted to $220.5 million in Q3 2025, which was up 6214.09% from $101.5 million recorded in Q2 2025.
- Compass Therapeutics' Cash & Current Investments' 5-year high stood at $220.5 million during Q3 2025, with a 5-year trough of $101.5 million in Q2 2025.
- Over the past 3 years, Compass Therapeutics' median Cash & Current Investments value was $152.5 million (recorded in 2023), while the average stood at $152.8 million.
- Examining YoY changes over the last 5 years, Compass Therapeutics' Cash & Current Investments showed a top increase of 6214.09% in 2025 and a maximum decrease of 3570.35% in 2025.
- Quarter analysis of 3 years shows Compass Therapeutics' Cash & Current Investments stood at $152.5 million in 2023, then dropped by 16.51% to $127.3 million in 2024, then skyrocketed by 73.2% to $220.5 million in 2025.
- Its Cash & Current Investments was $220.5 million in Q3 2025, compared to $101.5 million in Q2 2025 and $113.2 million in Q1 2025.